Aggressive surgical resection followed by adjuvant therapy consisting of (chemo)radiation is the mainstay of treatment for squamous cell carcinoma of the head and neck (SCCHN). Despite these treatments, SCCHN is a devastating disease that portends an overall 5-year survival of only ~50%. There is therefore a need to identify novel strategies and drug combinations to treat SCCHN.